Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment

被引：0
|
作者：
Rexer, H. [1 ,3 ]
Ohlmann, C. -H. [2 ]
Grimm, M. -O.
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Deutsch Krebsgesellschaft eV, Arbeitsgemeinschaft Urol Onkol, Berlin, Germany
[3] AUO Geschaftsstelle Frau Heidrun Rexer ViSdP, MeckEvidence H Rexer Seestr 11, D-17252 Schwarz, Germany
来源：
UROLOGIE | 2023年 / 62卷 / 03期
关键词：
D O I：
10.1007/s00120-023-02056-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 339
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [22] Intravesical BCG therapy for non-muscle invasive bladder cancer
    Figurin, K. M.
    ONKOUROLOGIYA, 2012, 8 (01): : 14 - 22
  • [23] Urinary cytokine profiles reflect rationale for treatment with gemcitabine and Bacillus Calmette-Guerin (BCG) in BCG-exposed high-risk non-muscle invasive bladder cancer (NMIBC)
    Gaffney, Christopher D.
    Alam, Syed M.
    Lavery, Jessica A.
    Basar, Merve
    D'Souza, Neeta
    Hernandez, Christian
    McCarter, Melissa
    Moran, Patricia
    Stasi, Kristen
    Worth, Kara
    Sjoberg, Daniel
    Dalbagni, Guido
    Donahue, Timothy
    Donat, Sherri
    Bajorin, Dean
    Bochner, Bernard H.
    Goh, Alvin
    Sarungbam, Judy
    Al-Ahmadie, Hikmat
    Pietzak, Eugene J.
    CLINICAL CANCER RESEARCH, 2024, 30 (10)
  • [24] Bacillus Calmette-Guerin (BCG) and alternatives Drug treatment of high-risk non-muscle invasive bladder cancer
    Leucht, K.
    Foller, S.
    Grimm, Marc-Oliver
    UROLOGE, 2021, 60 (11): : 1400 - 1408
  • [25] New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
    Asimakopoulos, Anastasios D.
    Kochergin, Maxim
    Colalillo, Gaia
    Fahmy, Omar
    Hassan, Fahmy
    Renninger, Markus
    Gallioli, Andrea
    Gavrilov, Pavel
    Gakis, Georgios
    BLADDER CANCER, 2023, 9 (03) : 237 - 251
  • [26] TRUCE04: A Phase II clinical trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) 24)
    Hu, H.
    Guo, S.
    Shen, C.
    Huang, S.
    Zhao, G.
    Zhang, Z.
    Wu, Z.
    Chen, H.
    Chen, H.
    Liang, S.
    Yuanjie, N.
    EUROPEAN UROLOGY, 2024, 85 : S1711 - S1711
  • [27] The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer
    Bola, Becky
    Hoskin, Peter J.
    Sangar, Vijay
    Choudhury, Ananya
    CANCERS, 2025, 17 (04)
  • [28] Genomic characterization of high-risk non-muscle invasive bladder cancer
    Meeks, Joshua J.
    Carneiro, Benedito A.
    Pai, Sachin G.
    Oberlin, Daniel T.
    Rademaker, Alfred
    Fedorchak, Kyle
    Balasubramanian, Sohail
    Elvin, Julia
    Beaubier, Nike
    Giles, Francis J.
    ONCOTARGET, 2016, 7 (46) : 75176 - 75184
  • [29] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Bashir Al Hussein Al Awamlh
    Sam S. Chang
    Current Oncology Reports, 2023, 25 : 83 - 91
  • [30] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Al Awamlh, Bashir Al Hussein
    Chang, Sam S.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (02) : 83 - 91
12345